Science子刊:一类降糖药物虽不增加肿瘤风险,但促进肿瘤转移

2016-04-17 MedSci MedSci原创

中国研究人员一项新研究显示,糖尿病药物中的抗氧化剂有可能会促使肿瘤扩散,这提示医生不要给同时罹患糖尿病与肿瘤的患者滥用抗氧化剂。 这项研究4月13日发表在新一期美国《科学转化医学》杂志上,两名研究负责人是第三军医大学新桥医院内分泌科主任郑宏庭和第三军医大学西南医院副主任医师余时沧。 他们介绍说,大量证据表明糖尿病增加多种肿瘤的发生风险,因此糖尿病合并肿瘤患者日益增多。这些患者也需采取降

中国研究人员一项新研究显示,糖尿病药物中的抗氧化剂有可能会促使肿瘤扩散,这提示医生不要给同时罹患糖尿病与肿瘤的患者滥用抗氧化剂。

这项研究4月13日发表在新一期美国《科学转化医学》杂志上,两名研究负责人是第三军医大学新桥医院内分泌科主任郑宏庭和第三军医大学西南医院副主任医师余时沧。

他们介绍说,大量证据表明糖尿病增加多种肿瘤的发生风险,因此糖尿病合并肿瘤患者日益增多。这些患者也需采取降糖治疗,然而降糖治疗有可能通过多种途径对肿瘤的生物学行为产生潜在影响。因此,科学评价这种影响,对糖尿病合并肿瘤患者的合理用药具有重要意义。

小鼠实验发现,目前广泛应用的降糖药物---DDP4抑制剂saxagliptin 和sitagliptin,也作为一种ALA,虽然不增加肿瘤发生,但却可以促进肿瘤转移。降糖药物中的一些抗氧化剂虽然不会诱导新生肿瘤的发生,但会增加已有肿瘤转移的风险,其中包括结肠癌和肝癌。这提示糖尿病合并肿瘤患者在使用这些药物时需谨慎评估。

进一步研究揭示了这种现象的发生机制,即这些降糖药物是通过激活抗氧化信号通路NRF2,促进肿瘤转移与侵袭。氧自由基在肿瘤中是双面角色(Cancer Cell:与恶魔共舞的活性氧自由基

《科学转化医学》杂志此前刊登的另一项研究也显示,包括维生素E在内的抗氧化剂会增加烟民等高危人群患肺癌的风险(STM:吸烟者服用维生素增加患癌风险)。


 
当然,大部分研究认为抗氧化剂可以减少肿瘤的发生,如Science:震惊!300个橙子产生的维生素C,可以破坏癌细胞!

原始出处:

Wang H, Liu X, Long M, Huang Y, Zhang L, Zhang R, Zheng Y, Liao X, Wang Y, Liao Q, Li W, Tang Z, Tong Q, Wang X, Fang F, de la Vega MR, Ouyang Q, Zhang DD, Yu S, Zheng H. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med. 2016 Apr 13;8(334):334ra51

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-25 1dea6088m20(暂无匿称)

    抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-19 李继凯

    文章高大上

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-19 jichang
  7. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2026015, encodeId=08a2202601591, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Sep 21 19:58:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82716, encodeId=89e482e167b, content=抗氧化剂通常是防肿瘤发生相关的,抗氧化剂有使肿瘤扩散的机制研究结论哪些, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8231711773, createdName=1dea6088m20(暂无匿称), createdTime=Mon Apr 25 12:50:00 CST 2016, time=2016-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79704, encodeId=d301e970431, content=文章高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:12:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270826, encodeId=051012e082628, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291619, encodeId=56191291619d6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375214, encodeId=cd7813e52141e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390252, encodeId=2f1f139025224, content=<a href='/topic/show?id=355398180af' target=_blank style='color:#2F92EE;'>#降糖药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98180, encryptionId=355398180af, topicName=降糖药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Tue Apr 19 01:58:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79227, encodeId=b2b6e922791, content=对肿瘤患者应该慎用, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sun Apr 17 11:35:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 dhzzm

    对肿瘤患者应该慎用

    0

相关资讯

FDA批准降糖药empagliflozin上市

8月1日,美国食品与药物管理局(FDA)批准了empagliflozin片剂用于辅助改善饮食和运动控制不佳的2型糖尿病成人患者的血糖水平。FDA相关人员表示,该药可单独或作为整体降糖方案中的补充治疗。 Empagliflozin是钠葡萄糖共同转运蛋白2(SGLT2)抑制剂。FDA相关通告写道,该药不应用于以下类型患者:1型糖尿病、血或尿酮体升高(糖尿病酮症酸中毒)、严重肾脏损害、终末期肾病或

BMJ:不同降糖药导致不同并发症的风险大不相同

 糖尿病常常伴有多种并发症,病情恶化时常常会导致患者截肢、失明、肾损伤和高糖血症等,往往给病患和家属带来巨大的伤痛以及经济上的负担。为了评价二型糖尿病患者的截肢、失明、严重肾损伤、高糖血症和低糖血症与处方降糖药之间的联系,尤其是新近上市的药物格列汀和格列酮类降糖药物,研究人员开展了一项初级护理的开放队列研究。 在2007年4月1日到2015年1月31日间,共有469688名二型

胰岛素和新型降糖药的机会在哪?

作为临床常见的慢病之一,糖尿病困扰着大量患者及其家人。根据最新的IDF(国际糖尿病联盟)“IDF全球糖尿病地图”统计报告,目前全球20~79岁人群的糖尿病患病率为8.3%。 一般观念认为中国的糖尿病发病率低于西方国家的水平,但是,21世纪的新千年以来,中国的糖尿病发病率正飞速提升——2001年的数据是5.5%,2007年是9.7%,而最新的2013年中国糖尿病患病率调查的报告显示中国成人

详解各类降糖药优缺点比较

评价一种降糖药物的优劣,需要全面衡量,不能光看降糖效果,还要看安全性、耐受性、依从性、价格因素以及是否具有心血管保护作用等等。 1、磺脲类的优缺点 磺脲类降糖药是使用最早、应用最广的口服降糖药,主要通过刺激胰岛分泌胰岛素,增加体内胰岛素水平降低血糖。临床常用的有糖适平、达美康、优降糖、美吡达、亚莫利等。 优点:疗效突出、价格便宜,是2型糖尿病一线用药,对心血管无不良影响,没有癌症风险。

EASD 2014:强化降糖未能使大血管长期获益

研究简介ADVANCE 研究纳入11140 例年龄≥55 岁的2型糖尿病患者(病程>10年),随机分入标准血糖控制组或强化血糖控制组。强化治疗组接受格列齐特缓释片联合其他药物,以将糖化血红蛋白(HbA1c) 控制在≤6.5%。主要终点为主要大血管事件及微血管事件。中位随访5年后,强化治疗组平均HbA1c(6.5%)显著低于标准治疗组(7.3%)。强化治疗组可降低主要大血管和微血管事件复合发生率(1